Skip to main content
SpringerLink
Log in

Hypophosphatemic rickets: results of a long-term follow-up

  • Original Article
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

This study reports the benefits and side effects of conventional treatment, phosphate and calcitriol supplementation in patients with heritable hypophosphatemic rickets and a long-term follow-up, median of 60.9 months. The group is composed of 17 patients (ten girls). Sixteen patients presented with bone pain and/or deformities, and in one patient the diagnosis was radiological. All the patients had increased alkaline phosphatase, hypophosphatemia, decreased fractional phosphate tubular reabsorption (TRP) and maximum tubular phosphate reabsorption/glomerular filtration rate ratio (TPO4/GFR). Ten of 17 patients had metabolic acidosis, which was corrected only with the conventional treatment. Potassium citrate was prescribed to the patients who developed hypercalciuria. Excluding one patient with pulmonary dysfunction, the remaining 16 patients were divided into two groups according to the age at treatment onset (T0): group I (GI) ≥4 years (n =9) and GII <4 years (n =7). GI and GII had similar follow-up periods and treatment protocols. Seven out of nine GI patients underwent orthopedic surgery, in contrast to none of GII. Anthropometric data results showed that within each group there is no difference in weight and stature z -score at T0 and at the end of the observation (Tf), but, when both groups are compared, GII shows higher z -score for stature at T0 (p <0.05) and at Tf (p <0.05). Nephrocalcinosis developed in three cases and correlated with hypercalciuria (p <0.001) and dose of calcitriol (p =0.03). In conclusion, higher stature z -score is associated with early treatment. A careful protocol is recommended to detect such complications as nephrocalcinosis. We suggest potassium citrate for patients with hypercalciuria to avoid calcium precipitation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Tenehouse HS, Murer H (2003) Disorders of renal tubular phosphate transport. J Am Soc Nephrol 14:240–247

    Article  PubMed  Google Scholar 

  2. Kronenberg HM (2002) NPT2a—The key to phosphate homeostasis. N Eng J Med 347:1022–1024

    Article  Google Scholar 

  3. Takeda E, Yamamoto H, Nashiki K, Sato T, Arai H, Taketani Y (2004) Inorganic phosphate homeostasis and the role of dietary phosphorus. J Cell Mol Med 8:191–201

    PubMed  Google Scholar 

  4. Nenet-Pages A, Lorenz-Depiereux B, Zischka H, White KE, Econs MJ, Strom TM (2004) FGF-23 is processed by proprotein convertase but not by PHEX. Bone 35:455–462

    Article  PubMed  Google Scholar 

  5. Liu S, Guo R, Simpson LG, Kiao ZS, Burnham CE, Quarles LD (2003) Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem 278(39):37419–37426

    Article  PubMed  Google Scholar 

  6. White KE, Carn GC, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ (2001) Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 60:2079–2086

    Article  PubMed  Google Scholar 

  7. Bowe AE, Finnegan R, Beur SMJ, Cho J, Levine MA, Kumar R, Schiavi SC (2001) FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem Biophys Res Commun 284:977–981

    Article  PubMed  Google Scholar 

  8. Quarles LD (2003) FGF-23, PHEX and MEPE regulation of phosphate homeostasis and skeletal mineralization. Am J Physiol Endocrinol Metab 285:E1–E9

    PubMed  Google Scholar 

  9. Kruse A, Dracht U, Gopfert G (1982) Renal threshold phosphate concentration (TmPO4/GFR) Arch Dis Child 57:217–223

    Google Scholar 

  10. Brodehl J, Krause A, Hoyer P (1988) Assessment of maximal tubular phosphate reabsorption: Comparison of direct measurement with the nomogram of Bijvoet. Pediatr Nephrol 2:183–189

    Article  PubMed  Google Scholar 

  11. Patriquin H, Robitaille P (1986) Renal calcium deposition in children: sonographic demonstration of the Anderson-Carr progression. AJR Am J Roentgenol 146:1253–1256

    PubMed  Google Scholar 

  12. Kooh SW, Binet A, Daneman A (1994) Nephrocalcinosis in X-linked hypophosphatemic rickets: its relationship to treatment, kidney function, and growth. Clin Invest Med 17:123–130

    PubMed  Google Scholar 

  13. Friedman NE, Lobaugh B, Drezner MK (1993) Effects of calcitriol and phosphorus therapy on the growth of patients with X-linked hypophosphatemia. J Clin Endocrinol Metab 76:839–844

    Article  PubMed  Google Scholar 

  14. Doria A, Kooh SW, Cole WG, Daneman A, Sochett E (2003) Early treatment improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets. J Clin Endocrinol Metab 88:3591–3597

    Article  PubMed  Google Scholar 

  15. Patzer L, van’t Hoff W, Shah V, Hallson P, Kasidas GP, Samuell C, de Bruyn R, Barrat TM, Dillon MJ (1999) Urinary supersaturation of calcium oxalate and phosphate in patients with X-linked hypophosphatemic rickets and in healthy schoolchildren. J Pediatr 135:611–617

    PubMed  Google Scholar 

  16. Reusz GS, Latta K, Hoyer PF, Byrd DJ, Ehrich JH, Brodehl J (1990) Evidence suggesting hyperoxaluria as a cause of nephrocalcinosis in phosphate-treated rickets. Lancet 335:1240–1243

    Article  PubMed  Google Scholar 

  17. Schonaue E, Kruse K, Bohles HJ, Sewell AC (1992) More evidence for hyperoxaluria in phosphate-treated X-linked familial hypophosphatemic rickets. Eur J Pediatr 151:390

    Article  Google Scholar 

  18. Reusz GS, Hoyer PF, Lucas M, Krohn HP, Ehrich JHH, Brodehl J (1990) X-Linked hypophosphatemic: treatment, height gain, and nephrocalcinosis. Arch Dis Child 65:1125–1128

    PubMed  Google Scholar 

  19. Alon U, Donaldson DL, Hellerstein S, Warady BA, Harris DJ (1992) Metabolic and histologic investigation of the nature of nephrocalcinosis in children with hypophosphatemic rickets and in the Hyp mouse. J Pediatr 120:899–905

    PubMed  Google Scholar 

  20. Goodyer PR, Kronick JB, Jequier S, Reade TM, Scriver CR (1987) Nephrocalcinosis and its relationship to treatment of hereditary rickets. J Pediatr 111:700–704

    PubMed  Google Scholar 

  21. Verge CF, Lam A, Simpson JM, Cowell CT, Hoeard NJ, Silink M (1991) Effects of therapy in X-linked hypophosphatemic rickets. N Eng J Med 325:1843–1848

    Google Scholar 

  22. Seikaly M, Browne R, Baum M (1996) Nephrocalcinosis is associated with renal tubular acidosis in children with X-linked hypophosphatemia. Pediatrics 97:91–93

    PubMed  Google Scholar 

  23. Minari M, Castellani A, Garella S (1984) Renal tubular acidosis associated with vitamin D-resistant rickets. Miner Electrolyte Metab 10:371–374

    PubMed  Google Scholar 

  24. Saggese G, Baroncelli GI, Bertelloni S, Perri G (1995) Long-term growth hormone treatment in children with renal hypophosphatemic rickets: Effects on growth, mineral metabolism, and bone density. J Pediatr 127:395–402

    PubMed  Google Scholar 

  25. Baroncelli GI, Bertelloni S, Ceccarelli C, Saggese G (2001) Effect of growth hormone treatment on final height, phosphate metabolism, and bone mineral density in children with X-linked hypophosphatemic rickets. J Pediatr 138:236–243

    Article  PubMed  Google Scholar 

  26. Reusz GS, Miltenyi G, Stubnya G, Szabo A, Horvath C, Byrd DJ, Peter F, Tulassay T (1997) X-linked hyperphosphatemia: effects of treatment with recombinant human growth hormone. Pediatr Nephrol 11:573–577

    Article  PubMed  Google Scholar 

  27. Haffner D, Wuhl E, Blum WF, Schaefer F, Mehls O (1995) Disproportionate growth following long-term growth hormone treatment in short children with X-linked hypophosphatemia. Eur J Pediatr 154:610–613

    PubMed  Google Scholar 

  28. Nissel R, Wuhl E, Mehls O (2004) Effects of growth hormone treatment on body proportions and final height among small children with X-linked hypophosphatemic rickets. Pediatrics 113:e593–596

    Article  PubMed  Google Scholar 

  29. Scott A, Rivkees AS, El-Hajj-Fuleihan G, Brown EM, Crawford JD (1992) Tertiary hyperparathyroidism during high phosphate therapy of familial hypophosphatemic rickets. J Clin Endocrinol Metab 75:1514–1518

    Article  PubMed  Google Scholar 

  30. Gosnell JE, Posen S, Reeve TS, Delbridge LW (2004) Parathyroidectomy for tertiary hyperparathyroidism associated with X-linked dominant hypophosphatemic rickets. Arch Surg 139:218–222

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pediatric Nephrology Unit, Instituto da Crianca Hospital das Clinicas-Faculdade de Medicina da Universidade de Sao Paulo, Rua Nicolau de Souza Queiroz 297/ 84, 04105-001, Sao Paulo, Brazil

    Maria Helena Vaisbich & Vera H. Koch

Authors
  1. Maria Helena Vaisbich
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vera H. Koch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maria Helena Vaisbich.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vaisbich, M.H., Koch, V.H. Hypophosphatemic rickets: results of a long-term follow-up. Pediatr Nephrol 21, 230–234 (2006). https://doi.org/10.1007/s00467-005-2077-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-005-2077-4

Keywords

Search

Navigation